logo

SLN

Silence Therapeutics·NASDAQ
--
--(--)
--
--(--)
2.63 / 10
Underperform

Fundamental evaluation presents subpar characteristics (2.6/10). Strengths encompass Revenue-MV and Profit-MV, balanced by issues in Current assets turnover ratio and Fixed assets turnover ratio. This justifies challenging view.

Fundamental(2.63)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-5.58
Score2/3
Weight25.22%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.71%
1M Return5.26%
Gross profit margin (%)
Value61.33
Score2/3
Weight2.74%
1M Return1.47%
Profit-MV
Value0.46
Score2/3
Weight16.55%
1M Return7.79%
PB-ROE
Value0.62
Score1/3
Weight15.28%
1M Return7.02%
Current assets turnover ratio
Value0.00
Score0/3
Weight-3.03%
1M Return-1.88%
Fixed assets turnover ratio
Value0.27
Score1/3
Weight-2.62%
1M Return-1.64%
Asset-MV
Value-0.50
Score1/3
Weight20.06%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight16.57%
1M Return7.73%
Net profit / Total profit (%)
Value100.01
Score0/3
Weight-0.49%
1M Return-0.30%
Is SLN undervalued or overvalued?
  • SLN scores 2.63/10 on fundamentals and holds a Premium valuation at present. Backed by its -73.86% ROE, -249.86% net margin, -3.48 P/E ratio, 3.03 P/B ratio, and 23.41% earnings growth, these metrics solidify its Underperform investment rating.